Noticias y Actividades de Anthos Therapeutics
Ejecutivos
Ver el organigrama con sus 20 ejecutivos principales
Biografías más buscadas en Anthos Therapeutics
Recientes movimientos de ejecutivos en Anthos Therapeutics
- Will Kane, President and Chief Commercial Officer, ha dejado la empresa (noticia publicada el 13 de mayo de 2025).
- Venkat Ramanan, Chief Financial Officer, ha dejado la empresa (noticia publicada el 13 de mayo de 2025).
- Venkat Ramanan, se ha incorporado a la empresa como Chief Financial Officer (noticia publicada el 1 de noviembre de 2024).
Haga clic aquí para ver otros movimientos en Anthos Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Anthos Therapeutics.
Biotecnología
Anthos Therapeutics tiene 2.350 competidores entre los que se incluyen Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) y Lonza (Suiza).
Popular M&A news in Biotecnología
- Sirius Therapeutics acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 16 de junio de 2025).
- BioNTech has announced the acquisition of CureVac (publicado el 12 de junio de 2025).
- SpliceBio acaba de anunciar una recaudación de fondos de 135 millones de dólares. (publicado el 11 de junio de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Anthos Therapeutics
- Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront - Anthos Therapeutics
- Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
- Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - Anthos Therapeutics
- Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion - Anthos Therapeutics
- Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with At
- Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - Anthos Therapeutics
- Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer - Anthos Therapeutics
- Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer - Anthos Therapeutics
- New anti-clotting medication reduces bleeding among people with atrial fibrillation
- New anti-clotting medication found to reduce bleeding among people with atrial fibrillation
- View more press releases Close
Redes sociales sobre Anthos Therapeutics
- Anthos Therapeutics en Wikipedia, Google News y Yahoo Finance
- Anthos Therapeutics en LinkedIn, Twitter y YouTube
